Navigation Links
CEL-SCI Scientist Invited to Discuss Plans to Launch Unique Manufacturing Process That Saves Cost While Enhancing the Shelf Life of Drugs at 5th Annual Aseptic Processing of Sterile Drug Products Conference
Date:6/16/2009

VIENNA, Va., June 16 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM) announced today that Eyal Talor, Ph.D., Senior Vice President of Research and Manufacturing at CEL-SCI, has accepted an invitation to be a featured speaker at the 5th Annual Aseptic Processing of Sterile Drug Products Conference to be held June 17th - 19th. The Conference, sponsored by The Institute of Validation Technology (IVT), takes place at the Sheraton National Hotel in Arlington, VA. At the workshop titled "Aseptic Facility Design Fundamentals - Cold Fill/Finish Design for a Biologic, Liquid Injectable", Dr. Talor will discuss the Company's plans to launch a unique manufacturing process that could allow drugs using stem cell technology and other biological products to maintain their potency through the entire manufacturing process, as well as enhance the shelf life of these drugs.

The availability of this unique aseptic filling process developed by CEL-SCI may also significantly accelerate the time to market by eliminating complicated, costly and time consuming validation studies and tests required when these products are filled at room temperature. This process is also likely to save money in the production of follow-on biologics and biosimilars (the general equivalent of generics in the biological arena) likely to be approved in the U.S. soon.

CEL-SCI's new state-of-the-art manufacturing facility near Baltimore, Maryland, where CEL-SCI plans to manufacture its lead cancer product Multikine(R), will be offering this service to outside companies on a contract basis. The facility will allow CEL-SCI to perform aseptic filling of small volume parenteral drug products.

The Company will employ a process known as "true cold" +4 degrees Celsius Aseptic Filling for products derived from stem cell technology, biotechn
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. CEL-SCI Expands Testing of Its Vaccine to Determine Efficacy Against More Virulent Strain of H1N1 Swine and Other Influenza Viruses
2. CEL-SCI Corporation Reports 2009 Second Fiscal Quarter Financial Results
3. CEL-SCI Announces Exclusive Licensing Agreement for Cancer Drug Multikine(R) for Republic of South Africa
4. CEL-SCI Launches Study to Determine Long Lasting Beneficial Effects of its Rheumatoid Arthritis Vaccine
5. CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
6. CEL-SCI Corporation Reports Second Quarter 2008 Financial Results
7. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
8. CEL-SCI Corporation Releases Letter to Shareholders
9. CEL-SCI Corporation Announces Adoption of Shareholder Rights Plan
10. Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
11. Scientists advance safety of nanotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... THURSDAY, July 10, 2014 (HealthDay News) -- Nature, not ... intelligence of individual chimpanzees, a new study finds. ... it comes to cognitive [thinking] abilities in chimpanzees," William ... Atlanta, said in a news release from the journal ... give insight into the evolution of intelligence in humans, ...
(Date:7/10/2014)... July 10, 2014 (HealthDay News) -- Men who have ... prostate cancer, a new study suggests. But the ... urologists not involved with the study said more research ... truly accurate. For the study, Harvard researchers analyzed ... followed for 24 years, starting in 1986. During that ...
(Date:7/10/2014)... than 200 experts on aggression, who research issues ranging ... the 21st World Meeting of the International Society for ... July 15-19. , Georgia State University is hosting the ... on alternating continents. , "We are excited to be ... countries, which will help produce fresh ideas about the ...
(Date:7/10/2014)... CLEVELAND The U.S. Department of Health and Human ... Hospitals (UH) Case Medical Center Seidman Cancer Center totaling ... at improving care for patients with complex cancer. ... a unique model developed at UH to enhance care ... or demonstrated need for high health care utilization. ...
(Date:7/10/2014)... studies have shown that more severe illness and even ... secondary respiratory infection after developing influenza. Now, however, a ... determined that if you reverse the order of infection, ... may actually protect against a bad case of the ... protein pneumolysin, which is described as a bacterial virulence ...
Breaking Medicine News(10 mins):Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Georgia State hosts national conference on aggression 2Health News:Georgia State hosts national conference on aggression 3Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Bacterial colonization prior to catching the flu may protect against severe illness 2
... Caraco Pharmaceutical,Laboratories, Ltd. (NYSE Alternext US: CPD) posted net ... first nine months of Fiscal 2009 of $55.7,million and ... million, respectively, for the third quarter and first nine ... the third quarter of Fiscal 2009,and an increase of ...
... study, presented at The Endocrine Society,s 90th Annual Meeting ... carbohydrates and protein followed by a low-carb, low-calorie diet ... dieters on track with their weight loss program.Lead author, ... Venezuela, along with scientists from Virginia Commonwealth University ...
... division of Ben Venue Laboratories, Inc., announced the ... AP rated and is equivalent to Camptosar(R).,Irinotecan is ... colon or,rectum whose disease has recurred or progressed ... for immediate shipment,nationwide. , ...
... RediClinic LLC today announced that it,has expanded its ... of Texas to include its Austin area clinics. ... an in-network provider for Blue Cross Blue,Shield enrollees. ... in,the Austin area and 15 H-E-B stores in ...
... 117 studies and 25,000 patients to arrive at ranking ... and escitalopram (Lexapro) are the best of 12 new-generation ... analysis shows. , The Italian researchers reviewed 117 studies ... to come to this conclusion. , The drugs tested ...
... First Substantive Legislation that would provide Comprehensive Pancreatic ... ProgressEL SEGUNDO, Calif., Jan. 29 The Pancreatic ... hope in a comprehensive way through research, patient ... applauds U.S. Representatives Anna Eshoo (D-CA) and Ginny ...
Cached Medicine News:Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 4Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 5Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 6Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 7Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 8Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 9Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009 10Health News:New Study: Protein in the Morning Helps Dieters Stay on Track and Keep Weight Off 2Health News:Bedford Laboratories(TM) to Begin Shipping Irinotecan HCl Injection 2Health News:RediClinic Locations in Austin Added as Blue Cross and Blue Shield of Texas Network Providers 2Health News:Zoloft, Lexapro the Best of Newer Antidepressants 2Health News:The Pancreatic Cancer Research and Education Act Addresses the Astounding Mortality of the Fourth Leading Cause of Cancer Death in the United States 2Health News:The Pancreatic Cancer Research and Education Act Addresses the Astounding Mortality of the Fourth Leading Cause of Cancer Death in the United States 3
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)... July 10, 2014  The U.S. Department of Health ... to University Hospitals (UH) Case Medical Center Seidman Cancer ... model aimed at improving care for patients with complex ... project will test a unique model developed at UH ... disease, significant comorbidities, or demonstrated need for high health ...
(Date:7/10/2014)... , July 10, 2014  Breg, Inc., ... services, has launched the FreeRunner™ knee brace with ... suffer from patella mal-tracking return to active lifestyles. ... than other braces, providing support when patients need ... when they don,t. Patellofemoral issues are ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2